Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 8,454,052 shares, a growth of 20.7% from the December 15th total of 7,001,428 shares. Approximately 13.9% of the shares of the stock are sold short. Based on an average daily volume of 1,459,903 shares, the short-interest ratio is presently 5.8 days. Based on an average daily volume of 1,459,903 shares, the short-interest ratio is presently 5.8 days. Approximately 13.9% of the shares of the stock are sold short.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the transaction, the chief executive officer directly owned 618,937 shares in the company, valued at approximately $14,538,830.13. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its position in Monte Rosa Therapeutics by 459.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the period. Vestal Point Capital LP acquired a new position in Monte Rosa Therapeutics during the 3rd quarter worth approximately $5,928,000. Marshall Wace LLP lifted its position in Monte Rosa Therapeutics by 102.4% during the 3rd quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock worth $6,690,000 after acquiring an additional 456,754 shares in the last quarter. Millennium Management LLC boosted its holdings in Monte Rosa Therapeutics by 588.4% in the 3rd quarter. Millennium Management LLC now owns 444,939 shares of the company’s stock worth $3,297,000 after acquiring an additional 380,308 shares during the period. Finally, American Century Companies Inc. grew its holdings in Monte Rosa Therapeutics by 301.4% during the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after purchasing an additional 302,639 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Down 1.5%

Shares of GLUE stock traded down $0.37 during trading hours on Monday, hitting $23.71. 865,917 shares of the company were exchanged, compared to its average volume of 2,628,357. The firm has a market cap of $1.54 billion, a PE ratio of 74.10 and a beta of 1.60. The firm has a fifty day moving average of $17.17 and a 200 day moving average of $10.49. Monte Rosa Therapeutics has a 1 year low of $3.50 and a 1 year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06. The firm had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $7.37 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%. Analysts expect that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on GLUE. Guggenheim increased their target price on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Piper Sandler restated an “overweight” rating and issued a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Finally, Wells Fargo & Company lifted their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $31.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.